An open-label study of fludarabine and cyclophosphamide plus MabThera (rituximab) followed by maintenance with MabThera on failure-free survival in treatment-naive patients with advanced indolent B-cell nonfollicular lymphoma.

Trial Profile

An open-label study of fludarabine and cyclophosphamide plus MabThera (rituximab) followed by maintenance with MabThera on failure-free survival in treatment-naive patients with advanced indolent B-cell nonfollicular lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 01 Jul 2010 Planned end date (1 Mar 2011) added as reported by ClinicalTrials.gov.
    • 01 Jul 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, NCT01153971).
    • 30 Jun 2010 Planned number of patients changed from 45 to 47 as reported by Roche record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top